Cannabis Based Pain Relief Solution Receives European Patent Approval

IGC Pharma, Inc. IGC has been granted European Patent No. 3193862 by the European Patent Office for its innovative "Cannabinoid Composition and Method for Treating Pain."

The newly granted patent introduces a pioneering method for treating pain in humans.

How It Works

Utilizing a cream base infused with a unique blend of cannabinoids, including tetrahydrocannabinol (THC) and cannabidiol (CBD) as well as other compounds, the cream or gel is designed for transdermal absorption.

It interacts harmoniously with the peripheral nervous and immune systems, effectively relieving pain without psychotropic or adverse side effects.

Recent consumer trends indicate a profound demand for safe and effective pain relief, and IGC Pharma is seeking to advance pain relief therapies, said Ram Mukunda, the company's CEO.

"We aspire to redefine the standard for pain management, providing healthier alternatives to traditional medications," Makunda continued.

Read also: Cannabis Effective For Chronic Pain, Substituting Opioids: Johns Hopkins & Univ. Of Michigan Study Confirms

Alternative Solution For Pain Management

In America alone, over 56 million individuals grapple with debilitating arthritis, while 10 to 30% of total joint arthroplasty patients endure persistent pain. Health economists estimated the annual cost of pain management in the U.S. ranged from $560 billion to $635 billion in 2012, the company said, citing the Journal of Pain's data.

"Our portfolio now boasts an impressive 35 patent filings in various countries, including the U.S. and Canada," Makunda said. "I believe that our innovative approach to pain relief has the potential to disrupt the industry, providing investors with a unique chance to be part of a transformative journey. With a substantial addressable market and a strong intellectual property portfolio, we are well-positioned for growth."

Now read: After 17 Years Of Side Effects From Standard Drugs, Chronic Pain Patient Finds Relief With Cannabis: Study

Missed the first wave of cannabis investments? Don’t make that mistake again.
Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth. Join Benzinga PotProfits. Benefit from Michael Berger’s sharp analysis, revealing top cannabis stock opportunities and timely updates. Experience the potential of 10%+ returns in just 90 days. Our 4.5-star Marketfy rating speaks volumes. Secure your position in this booming sector with a 30-day money-back guarantee. The time to invest is now, before everyone else realizes it. Secure your profits with Benzinga. Click here now to learn more.

IGC Price Action

IGC’s shares traded 6.66% lower at $0.3001 per share during the pre-market session on Friday morning

Photo: Courtesy of Towfiqu barbhuiya on Unsplash